pharma news today glp-1 obesity A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio GLP-1 Agonists Weight Loss Drugs

In general, though, Aetna plans vary in their coverage of Zepbound for OSA

4.7 Pregnancy-related effects Although type 2 diabetes and obesity have been effectively treated with GLP-1 receptor agonists, their role in pregnancy and breastfeeding has been a controversial debate due to potential risks to the mothers health and fetal outcomes (87)

brand Wegovy and oral Rybelsus remain Novo Nordisk products, while Eli Lilly's tirzepatide products Mounjaro and Zepbound are not affected by the semaglutide generic decisions

Aghili SMM et al (2021) Obesity in COVID-19 era, implications for mechanisms, comorbidities, and prognosis: a review and meta-analysis

This shift opens a meaningful growth opportunity for CPG manufacturers ready to reframe indulgence as functional. The Food Institute Podcast At SIAL Canada 2026 in Montreal, Food Institute VP of Content and Insights Chris Campbell sat down with Mathieu Brisson, Global Sales Lead at Prestige Maple , to discuss how the company is transforming maple products for a rapidly evolving global food and beverage market.

For the general adult population, the recommended daily allowance for protein is 0.8 g per kg of body weight per day [152]